

Joe Lombardo  
Governor

Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
*Helping people. It's who we are and what we do.*



Stacie Weeks,  
JD MPH  
Administrator

**Silver State Scripts Board Meeting Minutes**

**Date of Meeting:** Thursday, March 23, 2023, at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																											
<b>1. Closed Executive Session</b>																													
<p><b>a. Call to Order and Roll Call</b></p>	<p>Chairperson Mark Decerbo called the meeting to order at 1:20 p.m. on March 23, 2023.</p> <p>Chairperson Decerbo took the roll.</p> <table border="0" data-bbox="688 800 1541 1170"> <thead> <tr> <th></th> <th style="text-align: center;">Present</th> <th style="text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm. D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Griffin, Karen, Deputy Attorney General</li> <li>• Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>• Olsen, David, Social Services Chief III</li> <li>• Gudino, Antonio, Social Services Program Specialist III (SSPS)</li> <li>• Berntson, Kindra, SSPS II</li> <li>• Flowers, Ellen, Program Officer I (PO)</li> </ul> <p><b>Magellan Rx Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>• Kim, James, Pharm.D.,</li> </ul>
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

		<p>Dir. Clinical Account Services</p> <ul style="list-style-type: none"> <li>• Martinez, Chris, Sr. Business Analyst</li> <li>• Chow, Connie, Pharm.D., Clinical Account Manager</li> <li>• Perez, Melissa Sr. Business Analyst</li> </ul>
<p><b>b. Financial Review of Drug Classes with Proposed Changes</b></p>	<p>Chairman Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review.</p> <p>Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</p> <p>Dr. Mishra presented the Financial Review of the News Drugs, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> <li>• Immunomodulators</li> <li>• Antipsoriatic Agents</li> </ul> <p>Dr. Mishra presented the Financial Review of the Established Drug Classes Being Reviewed due to Release of New Generics, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> <li>• Anticoagulants, oral</li> <li>• Otic Anti-infectives- Otic Quinolones</li> </ul> <p>Dr. Mishra presented the Financial Review of the Established Drug Classes with Proposed Changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> <li>• Gastrointestinal Agents- Functional Gastrointestinal Disorder Drugs</li> <li>• Dermatologic Agents- Topical Antivirals</li> <li>• Ophthalmic Anti-infectives - Ophthalmic Quinolones;</li> </ul>	

	<p>Ophthalmic Macrolides</p> <ul style="list-style-type: none"> <li>• Cardiovascular Agents- Beta-Blockers</li> <li>• Antihistamines- H1 Blockers Non-Sedating</li> <li>• Respiratory Agents- Glucocorticoids/LABA combination products</li> </ul>																												
<b>2. Open Public Meeting</b>																													
<p><b>a. Call to Order and Roll Call</b></p>	<p>Chairman Decerbo called the meeting to order at 1:55 p.m. on March 23, 2023.</p> <p>A quorum was present.</p> <p>Chairman Decerbo took the roll.</p> <table data-bbox="688 665 1470 1039"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm. D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Griffin, Karen, Deputy Attorney General</li> <li>• Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>• Olsen, David, Social Services Chief III</li> <li>• Gudino, Antonio, SSPS III</li> <li>• Berntson, Kindra, SSPS II, Pharmacy Unit</li> <li>• Ellen Flowers, PO I</li> </ul> <p><b>Magellan Rx Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>• Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>• Martinez, Chris, Sr. Business Analyst</li> <li>• Chow, Connie, Pharm.D., Clinical Account Manager</li> </ul> <p><b>The public attendee list is</b></p>
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

		<p><b>included as Attachment A.</b></p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured</p>
<p><b>b. Approval for previous Meeting Minutes from December 15, 2022</b></p>	<p>By unanimous consent, the minutes were approved as revised.</p>	
<p><b>c. Public Comments</b></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comments were provided.</p>	
<p><b>d. Status Update by DHCFP</b></p>	<p>Chief of Pharmacy Services, David Olsen, provided several announcements.</p> <ul style="list-style-type: none"> <li>• The 82nd legislative session is currently underway. Value legislature typically only meets an odd number of years. This session is currently scheduled to end on June 6th.</li> <li>• Beginning July 1st of 2023 providers should begin contacting Magellan to obtain prior authorization for specific drugs for the Fee-for-Service recipients would base of service on or after July 1st. Providers will be able to complete the prior authorization process through either web or phone. Prior authorization will be required for medical specialty drugs when they are administered in the following places of service physicians' offices, patient homes or outpatient facilities. The list of drugs that will require prior authorization is limited to 60 and that is going to be posted within our Medicaid Services manual, Chapter 1200. Also in addition to the prior authorization program, there will be a fee schedule for physician administered drugs starting in June. Please check the rates page of the divisions website for more information. A public</li> </ul>	

	<p>hearing is scheduled on March 28th at 10:00 AM, which will include the physician administered drug fee schedule as an agenda item, The notice will be posted on our public notices web page. If there any questions, please feel welcome to contact the Nevada Medicaid pharmacy services team at the RX Info e-mail listed on the agenda, it's <a href="mailto:rxinfo@dncfp.Nv.gov">rxinfo@dncfp.Nv.gov</a>.</p> <ul style="list-style-type: none"> <li>The newly created Central Nevada Health District, has named Doctor Antonina Capurro as its first administrator. Doctor Capurro has served as the Deputy Administrator over Nevada Medicaid programs, including Pharmacy Services, she has supported and attended Silver State Scripts Board meetings for the past two years. Her last day with the division is tomorrow the 24th, so she will be greatly missed and we wish her well. She continues to serve Nevada.</li> </ul> <p>Manager of Pharmacy Services, Antonio Gudino, provided an announcement.</p> <ul style="list-style-type: none"> <li>As of April 1st of 2023, we have a new board member joining us. Doctor Leanna Ramirez and currently the Chief Clinical Officer at the LGBTQ Center of Southern Nevada, and she is a highly qualified pharmacist and talented leader with more than 10 years of experience in managing complex disease states and helping patients get complete pharmacy care to support their health goals and treatment plans. Doctor Ramirez's knowledge, experience and commitment to excellence will make an outstanding addition to the silver State Scripts Board and ensuring that Medicaid continues to provide high quality services to all eligible recipients. Welcome Doctor Ramirez.</li> </ul>	
<p><b>3. Clinical Presentations</b></p>		
<p><b>A.</b> For Possible Action: Discussion and possible adoption of</p>		

<p>Immunomodulators- Targeted Immunomodulators.</p>																										
<p>i. <u>Public comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Ben Droese pharmacist with Amgen medical affairs.</p> <p>Public comment was provided by Doctor KayOnda Bayo a field HR scientist, health economics and outcomes research scientists with Bristol-Myers Squibb.</p>																									
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra discussed Sotyktu, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Joseph Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Board Member Sapandeep Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 1198 1474 1414"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

	<ul style="list-style-type: none"> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	<p>Dr. Mishra recommended adding Sotyktu on the PDL as non-preferred.</p> <p>Moving Siliq to non-preferred.</p> <p>Adding Infliximab to preferred.</p> <p>Moving Avsola, Inflectra, Renflexis to non-preferred.</p> <p>Adding Amjevita to non-preferred and keeping the brand Humira as preferred.</p>																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice-Chair Kate Ward moved to approve the proposed changes as presented by Magellan with the exception moving Avsola, Inflectra, Renflexis to non-preferred and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

<p><b>B. For Possible Action: Discussion and possible adoption of Antipsoriatic Agents.</b></p>																																						
<p>i. <u>Public comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra discussed Zoryve, Vtama the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Elizabeth Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 987 1474 1318"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for</p>	<p>Dr. Mishra recommended adding Vtama and Zoryve on the PDL as non-preferred.</p>																																					



<p>PDL inclusion by MagellanRx</p>	<p>Moving calcipotriene cream to preferred.</p> <p>Moving brand Sorilux to non-preferred in place of the generic calcipotriene foam.</p> <p>Moving generic calcipotriene/ betamethasone susp to non-preferred and leaving the brand Taclonex as preferred.</p> <p>Removing Vectical ointment from PDL per policy due to manufacture in non-participation in the Medicaid rebate program.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to approve the proposed changes as presented by Magellan with the exception of moving also calcipotriene ointment and solution as preferred and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 914 1476 1247"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>C. For Possible Action: Discussion and possible adoption of Anticoagulants, oral</p>																																						

<p>i. <u>Public Comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra discussed the product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 880 1474 1214"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended adding dabigatran as non-preferred and leaving brand Pradaxa as preferred.</p> <p>Adding Pradaxa Oral Pellets as non-preferred.</p>																																					

	Adding Xarelto susp as preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
D. For Possible Action: Discussion and possible adoption of Otic Anti-infectives- Otic Quinolones.																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					

<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended adding ciprofloxacin/dexamethasone as non-preferred and leaving brand Ciprodex as preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																					
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none"> <li>● Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																	
<b>E.</b> For Possible Action: Discussion and possible adoption of Gastrointestinal Agents- Functional Gastrointestinal Disorder Drugs.																		
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																	
ii. Drug class review presentation by MagellanRx	<p>Dr. Mishra discussed Ibsrela the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border: none;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

	<ul style="list-style-type: none"> <li>● Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Sapandeeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Ibsrela to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo moved to approve the proposed changes as presented by Magellan with the exception of moving Movantik and Relistor syringe to preferred and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Sapandeeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
F. For Possible Action: Discussion and possible adoption of Dermatologic Agents- Topical Antivirals.																																						

<p>i. <u>Public Comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment provided.</p>																																					
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="688 808 1478 1143"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended moving Zovirax ointment to non-preferred in place of the generic acyclovir ointment.</p> <p>Adding penciclovir as non-preferred and leaving brand Denavir as preferred.</p>																																					

	Removing Abreva due to manufacture non-participation in the Medicaid rebate program and adding the generic docosanol OTC as preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<b>G.</b> For Possible Action: Discussion and possible adoption of Ophthalmic Anti-infectives - Ophthalmic Quinolones.																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					



<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 487 1470 820"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended to moving generic ofloxacin to preferred and adding brand Ocuflax as non-preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 1226 1470 1399"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none"> <li>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																													
<b>H.</b> For Possible Action: Discussion and possible adoption of Ophthalmic Anti-infectives - Ophthalmic Macrolides																														
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																													
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

	<ul style="list-style-type: none"> <li>● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Azasite to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo moved to approve proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
I. For Possible Action: Discussion and possible adoption of Beta-Blockers.																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					

<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 594 1474 928"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended moving generic propranolol/ HCTZ to non-preferred and adding brand Coreg CR as preferred.</p> <p>Moving Carvedilol ER from preferred to non-preferred.</p> <p>Adding propranolol solution as preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																																					

		<table> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
<b>J.</b> For Possible Action: Discussion and possible adoption of H1 Blockers Non-Sedating.																																							
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																						
ii. New Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																						
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																						
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				

	<ul style="list-style-type: none"> <li>● Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>● Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>																																					
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended moving cetirizine capsules OTC from preferred to non-preferred and leaving the Cetirizine tablets OTC as preferred.</p> <p>Moving cetirizine solution 5mg/5ml OTC from preferred to non-preferred and keeping the cetirizine solution 1mg/ml OTC as preferred.</p> <p>Adding fexofenadine D OTC as non-preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Gonzalez moved to approve the proposed changes by Magellan and Chairman Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Aditi Singh, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p><b>K.</b> For Possible Action: Discussion and possible adoption of Respiratory Agents-</p>																																						

Glucocorticoids/LABA combination products																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Chairman Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 844 1470 1177"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommending adding vilanterol/fluticasone as non-preferred and keeping the brand name Breo Ellipta as preferred.																																					

<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to approve the proposed changes as presented by Magellan and /Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 414 1480 755"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p><b>L.</b> MagellanRx Reports</p>	<p>MRx Pipeline- New Drugs to Market and New Line Extensions</p> <ul style="list-style-type: none"> <li>• On the Horizon</li> <li>• Infectious Disease</li> <li>• Endocrinology</li> <li>• Hematology</li> <li>• Biosimilar Overview</li> <li>• Humira Biosimilar Launch</li> </ul>																																					
<p><b>M.</b> Closing Discussion</p>																																						
<p>i. Public comments on any subject</p>	<p>No public comments were provided.</p>																																					
<p>ii. Date and location of the next meeting.</p>	<p>Date: June 22, 2023. Location: TBD</p>																																					
<p>iii. Adjournment</p>	<p>Chairman Decerbo adjourned the meeting at 2:58 PM.</p>																																					



**Attachment A – Members of the Public in Attendance**

Michael Z	Sarah Cowan	Joe Gelinas	Amy B-Teva
Joe Germain Jr.	Christopher Santarone	Christy Nguyen	Karen Sillas
Ben Droese	Jason	Rodney Cobb	KJ Jackson
KayOnda Bayo	Susan Hertzberg	Jeana Colabianchi	Gary Parentean
Karen Ou	Melissa Sommers	Luke Lim	Rodney Cobb

**Attachment B – Submitted Written Comment**

None

